Neonatal death due to pneumococcal infection · Pregnant women undergoing vaccination to prevent infant infection
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Pneumococcal colonization ‐ At 2‐3 months of age · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in pneumococcal colonization ‐ At 2‐3 months of age compared with control vaccine (low certainty).
1 finding from 1 review
Pneumococcal colonization ‐ By 6‐7 months of age · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in pneumococcal colonization ‐ By 6‐7 months of age compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection ‐ Pneumonia · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Pneumonia compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection ‐ Meningitis · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Meningitis compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection ‐ Otitis media · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Otitis media compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ All infections compared with control vaccine (low certainty).
1 finding from 1 review
CRM197‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
CRM197‐PCV7in high‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
OMPC‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV10in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Intervention not reported
Pneumococcal pneumonia, at least 1 episode · patients with COPD
The intervention showed no clear difference in pneumococcal pneumonia, at least 1 episode (low certainty).
1 finding from 1 review
Intervention not reported
Pneumonia, community acquired, at least 1 episode · patients with COPD
The intervention probably leads to lower pneumonia, community acquired, at least 1 episode (moderate certainty).
1 finding from 1 review
Intervention not reported
Death from cardiorespiratory causes · patients with COPD
The intervention showed no clear difference in death from cardiorespiratory causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with COPD
The intervention showed no clear difference in death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Hospital admission: any cause, at least 1 episode · patients with COPD
The intervention showed no clear difference in hospital admission: any cause, at least 1 episode (moderate certainty).
1 finding from 1 review
Intervention not reported
COPD exacerbation: at least 1 episode · patients with COPD
The intervention probably leads to lower COPD exacerbation: at least 1 episode (moderate certainty).
1 finding from 1 review